Daily Stock Analysis, CORN, CORIUM INTERNATIONAL INC, priceseries

CORIUM INTERNATIONAL INC. Daily Stock Analysis
Stock Information
Open
14.97
Close
14.77
High
14.95
Low
14.77
Previous Close
14.98
Daily Price Gain
-0.21
YTD High
16.44
YTD High Date
Jan 9, 2019
YTD Low
14.77
YTD Low Date
Apr 24, 2019
YTD Price Change
-1.35
YTD Gain
-8.37%
52 Week High
18.60
52 Week High Date
May 24, 2018
52 Week Low
14.77
52 Week Low Date
Apr 24, 2019
52 Week Price Change
-3.18
52 Week Gain
-17.72%
Company Information
Stock Symbol
CORN
Exchange
NASDAQ
Company URL
http://www.coriumgroup.com
Company Phone
650-298-8012
CEO
Peter D. Staple
Headquarters
California
Business Address
235 CONSTITUTION DRIVE, MENLO PARK, CA 94025
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001594337
About

Corium International, Inc. is a commercial stage biopharmaceutical company, which develops, manufactures and commercializes of specialty pharmaceutical products. The company development platforms enable transdermal delivery of large molecules or biologics, including vaccines, peptides and proteins, as well as small molecules that are otherwise difficult to deliver in a transdermal dosage form. Corium International was founded by Gary W. Cleary and Adrian L. Faasse, Jr. in 1995 and is headquartered in Menlo Park, CA.

Description

Corium International, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. It offers Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; and Crest Whitestrips for teeth whitening. The company's products under pipeline comprise Twirla, a combination hormonal contraceptive patch, that has completed Phase III clinical trial to deliver ethinyl estradiol and levonorgestrel hormones; MicroCor hPTH(1-34), a transdermal system that has completed Phase 1 and Phase II a clinical trial for the treatment of severe osteoporosis; and Donepezil and Memantine transdermal systems, which completed Phase I clinical trial for the treatment of Alzheimer's disease. In addition, it develops Aripiprazole TDS for the treatment for psychiatric disorders; Ropinirole TDS that is in preclinical stage for the treatment of Parkinson's disease; MicroCor Zolmitriptan that is in preclinical stage for treatment of migraine; and generic transdermal product for the prevention of nausea and vomiting associated with motion sickness. Corium International, Inc. has collaboration agreements primarily with The Procter & Gamble Company; Teva Pharmaceuticals USA, Inc.; Endo Pharmaceuticals, Inc.; Agile Therapeutics, Inc.; and Aequus Pharmaceuticals, Inc. The company was incorporated in 1995 and is headquartered in Menlo Park, California.